Quarterly ResultAug 5, 2026, 05:05 PM
BioAge Labs H1 2026 Net Loss $(48.35)M; Revenue $5.22M
AI Summary
BioAge Labs reported a net loss of $(48.35) million for the first six months of 2026, an increase from $(34.49) million in the same period last year, driven by higher research and development expenses. Collaboration revenue saw an increase to $5.22 million. The company significantly bolstered its financial position through a public offering in January 2026, raising $107.4 million, and an at-the-market program, adding $32.7 million, ensuring liquidity for at least the next year.
Key Highlights
- Reported net loss of $(48.35) million for the six months ended June 30, 2026, compared to $(34.49) million in 2025.
- Collaboration revenue for the six months ended June 30, 2026, was $5.22 million, up from $3.86 million in 2025.
- Research and development expenses increased to $44.78 million for H1 2026 from $30.95 million in H1 2025.
- Cash, cash equivalents, and marketable securities totaled $381.3 million as of June 30, 2026.
- Net proceeds from the January 2026 public offering were $107.4 million.
- Net proceeds from the at-the-market program were approximately $32.7 million as of June 30, 2026.
- Company expects current cash, cash equivalents, and marketable securities to fund operations for at least one year.
Price Impact
More from BIOA